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Up-regulation of Duffy antigen receptor expression in children families based on a cysteine motif located in the N-termi-
with renal disease. nal domain (C-X-C, C-C, and C) [1–5]. Chemokine re-
Background. The Duffy antigen chemokine receptor (DARC) ceptors are seven-membrane spanning proteins that typi-is a promiscuous chemokine receptor that binds chemokines
cally bind more than one chemokine from a given familyfrom the C-X-C and C-C families. DARC was initially de-
scribed on red blood cells, but subsequent studies have demon- and transmit signals across the membrane by interacting
strated DARC protein expression on renal endothelial and with G-coupled proteins [6]. In 1991, Darbonne et al
epithelial cells, even in Duffy-negative individuals whose red described an unusual chemokine receptor on red cell
cells lack DARC. Because approximately 68% of African
membranes that binds selected chemokines from bothAmericans lack the Duffy/DARC on their red cells, we carried
C-X-C and C-C families and that does not appear to beout experiments to identify the specific renal cells expressing
DARC protein and mRNA in African American children and coupled to a G protein [7–9]. The red cell chemokine
to define whether DARC expression was altered in renal in- receptor was shown to be identical to the Duffy blood
flammatory processes. group antigen and has been termed the Duffy antigenMethods. Immunohistochemistry and in situ hybridization
receptor for chemokines (DARC) [10–12]. DARC hasstudies were done in 28 renal sections from children with each
been shown to bind interleukin-8 (IL-8) and melanomaof the following diagnoses: HIV nephropathy (HIVAN), HIV-
associated hemolytic uremic syndrome (HIV-HUS), HIV in- growth stimulatory activity (MGSA) from the C-X-C
fection without renal disease, HIV-negative children without family and regulated upon activation in normal T cells
renal disease, and Argentinean children with classic HUS.
expressed and secreted (RANTES), and monocyteResults. The predominant localization of DARC mRNA
chemoattractant protein-1 (MCP-1) from the C-C familyand protein was found in endothelial cells underlying postcapil-
lary renal venules in all patients studied. However, DARC [10–13]. To date, signaling by DARC has not been dem-
mRNA and protein were significantly up-regulated in peritubu- onstrated, although DARC transfectants have been
lar and glomerular capillaries, collecting duct epithelial cells, shown to internalize ligands [14]. The physiological roleand interstitial inflammatory cells in children with HIVAN,
of DARC is not clearly defined, but it has been postu-HIV-HUS, and classic HUS.
lated that DARC acts as a sink or clearance mechanismConclusion. These findings support the notion that the renal
DARC is linked to the inflammatory cascade and that African for chemokines that it binds [7].
American children may be at risk of accumulating chemokines Duffy/DARC blood group determinants are carried
in renal tissues.
on a 35 to 43 kDa integral membrane glycoprotein of the
red cell membrane [15, 16]. The two principal antigens of
clinical interest, Fya and Fyb, are determined by an amino
Chemotactic cytokines (chemokines) play important acid polymorphism in the N-terminal extracellular do-
roles in the regulation of leukocyte trafficking and in- main [17–19]. The Duffy negative phenotype (Fy a– b–),
flammation [1–3]. Chemokines are classified into three
determined by a mutation in the promoter for the erythroid
transcript, is predominantly an African phenotype, and
approximately 68% of African Americans lack Duffy/Key words: chemokine receptor, inflammation, leukocyte trafficking,
Duffy/DARC phenotype, childhood renal disease. DARC on their red cells [20, 21]. The Duffy/DARC-
negative erythroid phenotype confers resistance against
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Handley et al studied formalin fixed tissues by immu- 1999 by the International Society of Nephrology
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nohistochemistry using an anti-DARC antibody gener- The diagnosis of HIV infection and renal disease was
done by standard clinical and pathologic criteria. In addi-ated by Riwom et al and observed that DARC is ex-
pressed by endothelial cells of postcapillary venules in tion, six renal sections derived from Argentinean chil-
dren in the acute stages of classic or diarrhea-associatedthe kidney [23, 24]. DARC was also demonstrated to
be prominently displayed by endothelial cells of splenic HUS (associated with Shiga-like toxins) were used.
These sections were used as controls to define whethersinusoids and on Purkinje neurons of the cerebellum [14,
25, 26]. When nonhematopoeitic tissue was examined children from a different racial background and renal
disease would modulate the renal DARC expression infrom Duffy-negative individuals whose red cells lacked
the Duffy blood group antigen and therefore lacked a similar manner. The diagnosis of classic HUS and HIV-
HUS was made according to standard clinical criteriaDARC, it was noted that the vascular expression of
DARC is maintained, indicating that the Duffy/DARC- [34, 35].
negative red cell phenotype is erythroid specific [ab-
Immunohistochemistrystract; Guo et al, Blood 88(Suppl 1):513a, 1996] [14].
Following the initial report on the expression of Paraffin sections were cut at 4 mm, deparaffinized, and
rehydrated. Sections were then heated twice for five min-DARC in kidney, Chaudhuri et al [27] used a different
anti-DARC antibody [28] and noted expression of utes each in 0.01 m sodium citrate (pH 6.0) in a microwave
oven (2450 MHz, 850 W) to augment antigen retrieval.DARC not only by endothelial cells of renal postcapil-
lary venules, but also by endothelial cells of capillaries The anti-Fy6 monoclonal antibody to the Duffy blood
group antigen that Riwom et al produced was used asand renal glomeruli, as well as by epithelial cells of renal
collecting tubules [27]. The discrepancy between the ini- primary antibody [23]. The specificity of this antibody has
been previously recognized in renal sections [24]. Immu-tial report and the subsequent report on DARC expres-
sion in kidney suggested that there may be differences nostaining was performed using a commercial streptavi-
din-biotin alkaline phosphatase complex DAKO LSABin the levels of expression of DARC among different
structures in the kidney. The anti-DARC antibody used kit (Dako, Carpinteria, CA, USA) or the Histotastin-
DSe double staining kit (Zymed, South San Francisco,in the initial report may not have been of sufficient affin-
ity to detect DARC in capillaries and collecting tubules CA, USA) for the Duffy-PCNA (mouse anti-prolifera-
tive cell nuclear antigen antibody from DAKO) colocali-of kidney. Also, it is possible that levels of expression of
DARC may vary depending on the pathologic condition zation studies, according to the manufacturer’s instruc-
tions. Sections were counterstained with hematoxylin.that affects the kidney. Neither study investigated the
expression of DARC in renal tissues under specific Negative controls were done by omitting the primary
antibody or using an irrelevant mouse monoclonal anti-pathological conditions or addressed the question of
whether DARC expression in kidney is up-regulated body. The intensity and distribution of Duffy antigen
by immunohistochemistry in each renal section wereby the inflammatory process. Thus, because chemokines
play a role in the pathogenesis of renal disease [29–33], counted in postvenule capillaries, glomerular capillaries,
renal tubular epithelial cells, and interstitial cells in fivewe examined the expression of DARC in children from
different renal diseases and racial backgrounds in com- different microscopic renal fields measuring 0.25 mm2 at
a magnification of 3200 using a grid in the eyepieceparison to normal kidneys. We found a significant up-
regulation of the DARC in renal tissues from children of the microscope. Renal DARC was quantitated by
counting the percentage of positive postcapillary ven-with HIV nephropathy (HIVAN) and hemolytic uremic
syndrome (HUS), independent of their racial back- ules, glomerular capillaries, collecting ducts, dilated tu-
bules, or cysts stained by the DARC antibody. A semi-ground. These findings suggest that DARC may play a
relevant role in the pathogenesis of renal inflammation. quantitative scoring system (0 to 3) was used: score 0 5
0 to 5%, score 1 5 6 to 20%, score 2 5 21 to 50%,
score 3 5 51 to 100% structures stained, respectively. All
METHODS
sections were scored independently by two investigators.
Patients Only sections stained under identical conditions were
compared. The number of DARC 1 interstitial cellsThis study was approved by the Institutional Review
Board from the Children’s National Medical Center. Re- was counted in similar renal areas, and the results were
expressed as the mean value of five different microscopicnal sections obtained at autopsy or renal biopsy from
HIV-infected children with the following diagnosis were fields.
used in this study: HIVAN (N 5 6), HIV-associated
In situ hybridizationHUS (3), HIV-infected children without renal disease
(7), and HIV-negative children without renal disease (6). The human Duffy antigen antisense and sense RNA
probes were synthesized and labeled by in vitro transcrip-All patients were younger than 12 years of age. Ninety
percent of all of these patients were African American. tion using digoxigenin-labeled uridine triphosphate. An
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approximately 1.2 kbp polymerase chain reaction prod- ined by light microscopy. The negative controls included:
(a) hybridization with the sense probe, (b) RNase (100uct of human Duffy antigen receptor was cloned into
the EcoR I site of the pCReII vector between SP6 and mg/ml in 10 mm Tris HCl, pH 8.0, 1 mm ethylenediamine-
tetraacetic acid) pretreatment before hybridization, andT7 promoters. The plasmid was linearized with the ap-
propriate restriction enzymes, BamH1 (antisense human (c) omission of either the antisense RNA probe or the
anti-digoxigenin antibody. After subtraction of the non-Duffy antigen receptor, T7 RNA polymerase), and EcoRV
(sense human Duffy antigen receptor, SP6 RNA poly- specific background detected with the sense probe, posi-
tive renal structures or interstitial cells were counted andmerase) and was purified by phenol/chloroform extrac-
tion and ethanol precipitation. Linearized plasmid was quantitated as described earlier here for the immunohis-
tochemistry studies.resuspended in diethylpyrocarbinate (DEPC)-treated
water. Transcription of 1 mg linearized plasmid was per-
Statistical analysisformed using a DIG RNA-labeling Kit (Boehringer-
Mannheim Biochemica, Mannheim, Germany). The re- All values are expressed as mean 6 sd. Statistical
significance was evaluated using Students’ test or one-action products were ethanol precipitated and stored at
2708C until used. The labeling efficiency of the ribo- way analysis of variance with modified t-test using the
Bonferroni method. P values of less than 0.05 were con-probe was estimated by comparison with a 10-fold serial
dilution of a digoxigenin-labeled control riboprobe and sidered statistically significant.
direct detection of the labeled riboprobe with antidigoxi-
genin antibodies. Riboprobe concentrations were ad-
RESULTS
justed to be equivalent on the basis of the labeling effi-
Immunohistochemistryciency before use in the in situ hybridization studies.
Ten-percent neutral buffered formalin-fixed and par- By immunohistochemistry studies using the murine
monoclonal anti-Fy6 antibody produced by Riwon et alaffin-embedded renal tissues were cut at 4 mm and were
floated onto 2% 3-aminopropyltriethoxysilane (APES; [23], which reacts with a peptide epitope that maps to
the N-terminal extracellular domain of Duffy/DARCSigma Chemical, St. Louis, MO, USA) coated slides.
Sections were heat fixed for 30 minutes at 658C and were [36, 37], the staining pattern was consistently localized to
endothelial cells underlying renal venules in all patientsdeparaffinized. After a 30-minute incubation in 5 mmol/
liter levamisole, the sections were washed in phosphate- studied (Fig. 1G). We found no differences in staining
intensity of renal venules from control and diseased kid-buffered saline (PBS) and in DEPC-treated water for
five minutes, respectively, and were then immersed in neys (Table 1). The intensity of DARC staining however,
was increased in glomerular capillaries, collecting ducts,0.2 mol/liter HCl for 20 minutes. Then the sections were
deproteinized by digestion with 20 to 40 mg/ml proteinase and interstitial cells of children with renal disease (Fig. 1
and Table 1). The up-regulation of renal DARC stainingK (Sigma) for 10 minutes at 378C, washed in 0.2% glycine
for five minutes twice, and in PBS for 10 minutes, and correlated with the pathologic findings. The highest
staining was detected in children with HIV-HUS, classicpostfixed with 1.5% paraformadehyde-1.5% glutaralde-
hyde for one minute. After rinsing twice for five minutes HUS, and HIVAN, whereas children with no evidence
of renal disease showed either no staining or faint stain-in PBS, sections were dehydrated through a graded etha-
nol series and air dried. The sections were hybridized ing in similar areas. Endothelial cells from arteries and
arterioles did not show any specific staining; however,with the RNA probes at the final concentrations of 0.1
to 0.5 ng/ml in 2 3 standard saline citrate (SSC), 10% some renal glomerular capillaries and fenestrated peritu-
bular capillaries in the cortex and medulla from childrendextran sulfate, 1 3 Denhardt’s solution, 20 mm Vanadyl
Ribonucleoside Complex (GIBCO BRL, Life Technolo- with classic HUS, HIV-HUS, and HIVAN were posi-
tively stained. Finally, some mononuclear cells infiltrat-gies, Gaithersburg, MD, USA), 0.1 m sodium phosphate
under sealed coverslips and incubated overnight in a ing renal glomeruli and peritubular interstitium in chil-
dren with renal disease showed positive staining (Tablemoist chamber at 428C. They were washed in 0.2 3 SSC
and then blocked with a blocking solution (50 mg/ml 1). Normal and diseased renal sections incubated with
an irrelevant mouse monoclonal antibody or omittingskimmed dried milk, 150 mm NaCl in 100 mm Tris HCl,
pH 7.8) at room temperature for 15 minutes, and the the first antibody did not show any significant staining
(data not shown).sections were incubated with anti-digoxigenin antibody
conjugated with alkaline phosphatase (Boehringer-Man-
In situ hybridization studiesnheim Biochemica) at the dilution of 1:750 for 30 minutes
at 378C. Colorimetric detection with nitro blue tetrazo- The in situ hybridization studies performed in renal
sections derived from the same patients confirmed thelium and 5-bromo-4-chloro-3-indolyl phosphate (Boeh-
ringer-Mannheim Biochemica) was then performed, and results obtained by immunohistochemistry. The steady-
state levels of DARC mRNA followed the same patternthe sections were mounted in 60% glycerol and exam-
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Table 1. Expression of renal DARC staining by immunohistochemistry using a semiquantitative visual scoring system and counting of the
percentage of positive capillaries, renal tubules, and the number of interstitial cells per 0.25 mm2 fields
Postcapillary venules Glomerular capillaries Renal tubular epithelial cells
% capillaries stained % capillaries stained/5 glom. % collecting ducts/cysts Interstitial cells
score 0–3 score 0–3 score 0–3 DARC1 cells/field
HIV-1 infection (N 5 7) 360.0 0.260.1 0.260.1 1.5 60.4
HIVAN (N 5 6) 360.0 1.060.2 2.360.1 2.7 60.6
HIV-HUS (N 5 3) 3 60.0 2.060.3 2.760.5 5.1 60.8
Classic-HUS (N 5 6) 3 60.0 2.060.2 2.660.3 3.0 60.2
Controls (N 5 6) 360.0 0.260.1 0.260.1 0.4 60.3
Data are mean 6 sd. Scores are: score 0 5 0–5%; score 1 5 6–20%; score 2 5 21–50%; score 3 5 51–100%. DARC1 interstitial cells were counted and expressed
as the mean number of cells per field. Abbreviations are: N, number of renal sections studied; HIV-infection, HIV-1 infected children without renal disease; HIVAN,
HIV-associated nephropathy; HIV-HUS, acute stage of HIV-associated hemolytic uremic syndrome; Classic HUS, Argentinean children in the acute stages of Shiga
toxin-induced hemolytic uremic syndrome; Controls, renal sections from HIV negative children without renal disease. With the exception of DARC expression in
postcapillary venules, all the data are related to HIVAN, HIV-HUS and Classic HUS are significantly different from the other two groups (P , 0.05).
Table 2. Expression of renal DARC staining by in situ hybridization using a semiquantitative visual scoring system and counting of the
percentage of positive capillaries, renal tubules, and the number of interstitial cells per 0.25 mm2 fields
Postcapillary venules Glomerular capillaries Renal tubular epithelial cells
% capillaries stained % capillaries stained/5 glom. % collecting ducts/cysts Interstitial cells
score 0–3 score 0–3 score 0–3 DARC1 cells/field
HIV-1 infection (N 5 7) 360.0 0.260.1 0.460.3 1.0 60.2
HIVAN (N 5 6) 360.0 1.660.4 2.560.5 2.3 60.4
HIV-HUS (N 5 3) 3 60.0 2.260.5 2.960.7 5.7 60.6
Classic-HUS (N 5 6) 3 60.0 2.460.4 2.860.5 3.2 60.4
Controls (N 5 6) 360.0 0.260.3 0.360.2 0.6 60.3
Data are mean 6 sd. Scores are: score 0 5 0–5%; score 1 5 6–20%; score 2 5 21–50%; score 3 5 51–100%. DARC1 interstitial cells were counted and expressed
as the mean number of cells per field. Abbreviations are: N, number of renal sections studied; HIV-infection, HIV-1 infected children without renal disease; HIVAN,
HIV-associated nephropathy; HIV-HUS, acute stage of HIV-associated hemolytic uremic syndrome; Classic HUS, Argentinean children in the acute stages of Shiga-
toxin-induced hemolytic uremic syndrome; Controls, renal sections from HIV-negative children without renal disease. With the exception of DARC expression in
postcapillary venules, all the data related to HIVAN, HIV-HUS and Classic HUS are significantly different from the other two groups (P , 0.05).
as the expression of DARC protein (Fig. 1 E, F, and DISCUSSION
Table 2). The highest and more consistent DARC In this study, we have shown that the promiscuous
mRNA staining was found in postcapillary venules (Fig. chemokine receptor DARC is expressed in postcapillary
2A), and no significant differences in DARC expression renal venules from all pediatric tissues studied, and that
were found between renal venules from control and dis- renal cells previously reported to stain with anti-DARC
eased kidneys. In contrast, DARC mRNA expression in antibodies [23, 24] actually produce the antigen as op-
glomerular capillaries (Fig. 2 B, C, E) and collecting duct posed to displaying the epitope by passive absorption.
epithelial cells (Fig. 3) was significantly up-regulated in In addition, we found that the expression of DARC
children with HIV-HUS, classic HUS, and HIVAN (Ta- within glomerular capillaries, collecting duct epithelial
ble 2). Moreover, epithelial cells underlying tubules un- cells, and interstitial cells is up-regulated in kidneys af-
dergoing microcystic changes (Fig. 3A) and peritubular fected by inflammation.
interstitial cells also revealed significant levels of DARC Using the anti-Fy6 monoclonal antibody produced by
mRNA staining. The specificity of these results was dem- Riwom et al, we observed different intensities of staining
onstrated by the absence of specific staining in renal in the different structures found to be positive for DARC
sections from diseased kidneys hybridized with the sense expression, suggesting different levels of expression by
the DARC-positive cells within these structures [23].DARC probe (Figs. 2D and 3B).
b
Fig. 1. Immunohistochemistry staining for the Duffy antigen chemokine receptor (DARC) in renal sections. (A) A representative DARC protein
staining from an HIV-infected child without renal disease. (B) A representative glomerular DARC protein staining in a child with HIVAN. (C
and D) DARC protein staining in collecting duct epithelial cells in an HIV-infected child without renal disease (C) and in a child with HIV-HUS
(D). (E and F) Colocalization staining of DARC mRNA (E) and DARC protein (F) by in situ hybridization (E, dark purple stain) and
immunohistochemistry (F, red stain) in two consecutive sections from a child with HIVAN. (G) DARC protein staining in renal glomeruli and
venules from a child with HIVAN. Note strong staining in renal venules. (H) DARC staining in a renal section from an Argentinean child with
Stx-HUS (magnification A–D, G–H 3300 and E–F 3360).
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Fig. 2. In situ hybridization studies for the Duffy antigen chemokine receptor (DARC) in renal sections. (A) Selective staining of DARC mRNA
in renal venules from an HIV-infected child without renal disease. (B and C) Recruitment of DARC mRNA in glomerular capillaries and interstitial
cells in renal sections from children with HIVAN and HIV-HUS hybridized with the DARC antisense probe. (D) A renal glomeruli from a child
with HIV-HUS hybridized with the DARC sense probe. (E and F) An in situ hybridization staining of DARC mRNA in children with HIVAN
(E) and HIV infection without renal disease (F) hybridized with the DARC antisense probe (magnification A–F 3360).
For example, endothelial cells of postcapillary venules plain why some endothelial or tubular epithelial cells
stain more positively than others. These changes may bestained more intensely than endothelial cells from glo-
merular capillaries and more intensely than epithelial due to the local chemokine/cytokine milieu or to changes
in the cell cycle, as the synthesis of DARC may be up-cells from collecting tubules. Currently, we cannot ex-
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Fig. 3. In situ hybridization studies for the Duffy antigen chemokine receptor (DARC) in the renal medulla of HIV-infected children. (A) DARC
mRNA staining in renal tubules undergoing tubular dilatation in a child with HIV-HUS hybridized with the antisense DARC probe. (B) A renal
section from the same child hybridized with the DARC sense probe. (C–E) Comparative DARC mRNA staining in collecting duct epithelial cells
from children with HIV-1 and renal cytomegalovirus infections (C), HIV-HUS (D), and HIV infection without renal disease (E). (F) A representative
colocalization staining of DARC protein (red stain) and anti-proliferative cell nuclear antigen (PCNA), dark purple stain, in collecting duct
epithelial cells from a child with HIV-HUS, with the anti-Fy6 DARC and mouse PCNA (Dako) antibodies (magnification A–F 3360).
regulated in proliferating cells. On the other hand, the specific role in this microanatomic location. Although
we did not know the Duffy/DARC red blood cell antigenstrong staining of postcapillary venules with anti-Fy6 in
all kidneys studied suggests that DARC may have a phenotype of the children whose kidney tissues we stud-
Liu et al: Renal DARC expression in children1498
ied, we used renal sections from children with different mononuclear cells results in a massive and rapid budding
of HIV virions toward the epithelium followed by theirracial backgrounds that should have different Duffy/
DARC red blood cell phenotypes [14, 20]. We found that internalization into epithelial endosome-like structures
[44]. Thus, chemokines by facilitating the recruitment ofDARC was expressed in all renal samples, confirming the
results of previous studies, which showed that the Duffy/ HIV-infected cells may play an important role in the
pathogenesis of HIVAN.DARC-negative red cell phenotype is erythroid specific
(abstract; Guo et al, ibid) [14]. In addition, this study Chemokines are basic proteins that can be sequestered
and immobilized via electrostatic interactions with nega-shows that renal injury induced by either HIV-1 or Shiga
toxins can up-regulate the synthesis of the renal DARC. tively charged glucosaminoglycans on the cell surface or
the extracellular matrix [1–3]. We have previously shownThese findings are in concordance with two preliminary
reports that showed up-regulation of DARC protein in an increased number of renal heparan sulfate proteogly-
can binding sites in HIV transgenic mice [40] and HIV-renal tissues from patients with necrotizing glomerulone-
phritis and class IV lupus nephritis (abstract; Rovin et al, infected children with renal disease (abstract; Ray et al,
J Am Soc Nephrol 7:A0480, 1996). Renal glycosamino-J Am Soc Nephrol 8:483A, A2246, 1997) and in inflamed
arteries or veins from other tissues (abstract; Guo et al, glycans in combination with DARC may help sequester-
ing chemokines from the circulation and increase theibid). Thus, it is possible that the expression of renal
DARC may be modulated by renal cytokines linked to recruitment of HIV-infected leukocytes [29–34]. DARC
itself does not specifically facilitate the entry of HIV-1the inflammation cascade.
Duffy antigen chemokine receptor has been postulated to susceptible cells; however, a recent preliminary study
has shown that HIV-1 can bind red blood cells fromto act as a sink for excess circulating chemokines [7].
This hypothesis was based on the findings that DARC Caucasian individuals via DARC (abstract; Lachgar et
al, 1998 Meeting Inst Human Virol Abstr Book 108:314,does not appear to flux calcium upon ligand binding, and
DARC on red cells does not internalize ligand [7]. Patho- 1998). This binding is inhibited by RANTES, and red
blood cells that do not express DARC fail to bind HIV-1logical states in which excess chemokines play a role
could theoretically be worse in Duffy/DARC-negative particles. In summary, DARC may modulate the cross
talk between HIV-1, chemokines, leukocytes, and renalindividuals, as the circulating chemokines available for
binding in renal tissues would theoretically be higher in endothelial/epithelial cells [45], and may increase the
susceptibility of these cells to HIV-1 infection as theDuffy/DARC-negative individuals who lack the red cell
chemokine “sink.” Considering that the Duffy/DARC- disease progresses. The localization of DARC on renal
glomerular capillaries and tubules undergoing microcys-negative red blood cell phenotype is predominately re-
stricted to African American patients [20, 22], an up- tic changes supports this hypothesis. Changes in DARC
expression may be associated with changes in capillaryregulation of renal DARC receptors in these patients
may facilitate the accumulation of chemokines in renal permeability leading to proteinuria and the release of
growth factors from endothelial cells [40, 46]. In supporttissues and may increase their risk of developing renal
injury [29–34]. As previously proposed by Schlo¨ndorff of this hypothesis, a recent study has shown that the
immobilization of IL-8 via its C terminus is required foret al [33], Duffy negative individuals may therefore be
more susceptible to HIVAN [38, 39]. This hypothesis is the induction of leukocyte emigration through endothelial
cells and suggests a cooperative interaction of heparansupported by the high levels of RANTES, IL-8, and
MCP-1b found in renal biopsies from patients with HI- sulfate proteoglycans (HSPG) and DARC in this process
[47]. On the other hand, it is possible that when a chemo-VAN, as these are the chemokines that normally would
bind to DARC on erythrocytes (abstract; Kimmel et al, kine binds to renal DARC it is no longer active and that
the renal DARC may also act as a sink inactivatingJ Am Soc Nephrol 5:279, 1994).
Studies in HIV-1 transgenic mice have shown that the chemokines [7]. This notion suggests that the up-regula-
tion of renal DARC might be an attempt by the kidneyexpression of HIV genes in renal epithelial cells can
induce clinical and renal histologic features similar to to down-regulate inflammation and to neutralize the ac-
tivity of chemokines. Thus, more studies are required toHIVAN [40–42]. We have shown that cultured primary
renal tubular epithelial cells could be infected by primary determine the specific role of DARC in the kidney.
In conclusion, our studies confirm the presence ofHIV-1 isolates derived from children with HIVAN [43].
Infected mononuclear cells established focal adhesion DARC protein and mRNA in endothelial cells of post-
capillary venules, glomerular capillaries, and collectingcontacts within underlying renal tubular epithelial cells
and released viral particles in the space between cells, tubules. Furthermore, we have demonstrated that the ex-
pression of DARC in the kidney is up-regulated by in-suggesting that interactions between both cell types may
facilitate the infection of renal epithelial cells [43]. In flammation, supporting the notion that DARC is linked
to the inflammation cascade. Finally, because HIVAN issupport of these findings, Bonsel has recently found that
the contact between epithelial cells and HIV-infected seen predominantly in African Americans and because
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S, Pogo AO: Cloning of glycoprotein D cDNA which encodes the68% of African Americans are Duffy negative, it is tempt-
major subunit of the Duffy blood group system and the receptor
ing to speculate that the Duffy/DARC-negative red for the Plasmodium vivax malaria parasite. Proc Natl Acad Sci
USA 90:10793–10797, 1993blood cell phenotype may be associated with the high
17. Iwamoto S, Omi T, Kajii E, Ikemoto S: Genomic organization ofincidence of HIVAN in African Americans [38, 39]. Fur-
the glycoprotein D gene: Duffy blood group Fya/Fyb alloantigen
ther studies, which include the Duffy typing of children system is associated with a polymorphism at the 44-amino acid
residue. Blood 85:622–626, 1995with HIVAN, are required to address this question.
18. Chaudhuri A, Polyakova J, Zbrzezna V, Pogo O: The coding
sequence of Duffy blood group gene in humans and simians: Re-
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